BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11029611)

  • 21. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
    Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
    J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of B7 costimulation in CD4/CD8 T cell homeostasis.
    Yu X; Fournier S; Allison JP; Sharpe AH; Hodes RJ
    J Immunol; 2000 Apr; 164(7):3543-53. PubMed ID: 10725709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4.
    Gerstmayer B; Pessara U; Wels W
    FEBS Lett; 1997 Apr; 407(1):63-8. PubMed ID: 9141482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
    Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
    J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of rat CD80 and CD86 by molecular cloning and mAb.
    Maeda K; Sato T; Azuma M; Yagita H; Okumura K
    Int Immunol; 1997 Jul; 9(7):993-1000. PubMed ID: 9237108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
    Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS
    J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules.
    Linsley PS; Nadler SG; Bajorath J; Peach R; Leung HT; Rogers J; Bradshaw J; Stebbins M; Leytze G; Brady W
    J Biol Chem; 1995 Jun; 270(25):15417-24. PubMed ID: 7541042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
    Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
    Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD80 expression is induced on activated B cells following stimulation by CD86.
    Sahoo NC; Rao KV; Natarajan K
    Scand J Immunol; 2002 Jun; 55(6):577-84. PubMed ID: 12028560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
    LaBelle JL; Hanke CA; Blazar BR; Truitt RL
    Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B70 antigen is a second ligand for CTLA-4 and CD28.
    Azuma M; Ito D; Yagita H; Okumura K; Phillips JH; Lanier LL; Somoza C
    Nature; 1993 Nov; 366(6450):76-9. PubMed ID: 7694153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis.
    Perrin PJ; Scott D; Davis TA; Gray GS; Doggett MJ; Abe R; June CH; Racke MK
    J Neuroimmunol; 1996 Mar; 65(1):31-9. PubMed ID: 8642061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
    van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
    Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
    [No Abstract]   [Full Text] [Related]  

  • 34. Differential expression of costimulatory molecules in chronic inflammatory periodontal disease tissue.
    Orima K; Yamazaki K; Aoyagi T; Hara K
    Clin Exp Immunol; 1999 Jan; 115(1):153-60. PubMed ID: 9933436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular cloning and expression of feline CD28 and CTLA-4 cDNA.
    Choi IS; Hash SM; Collisson EW
    Vet Immunol Immunopathol; 2000 Aug; 76(1-2):45-59. PubMed ID: 10973685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interaction properties of costimulatory molecules revisited.
    Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
    Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.
    Mandelbrot DA; Oosterwegel MA; Shimizu K; Yamada A; Freeman GJ; Mitchell RN; Sayegh MH; Sharpe AH
    J Clin Invest; 2001 Apr; 107(7):881-7. PubMed ID: 11285307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.
    Loser K; Scherer A; Krummen MB; Varga G; Higuchi T; Schwarz T; Sharpe AH; Grabbe S; Bluestone JA; Beissert S
    J Immunol; 2005 May; 174(9):5298-305. PubMed ID: 15843526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic organization of the gene coding for the costimulatory human B-lymphocyte antigen B7-2 (CD86).
    Jellis CL; Wang SS; Rennert P; Borriello F; Sharpe AH; Green NR; Gray GS
    Immunogenetics; 1995; 42(2):85-9. PubMed ID: 7541777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail.
    Leung HT; Bradshaw J; Cleaveland JS; Linsley PS
    J Biol Chem; 1995 Oct; 270(42):25107-14. PubMed ID: 7559643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.